SELLAS Life Sciences ($SLS) Stock Hub: $138.3 Million in Cash, SLS009 Topline Guided for Q4 2026, REGAL Still Waiting on Event 80

01 Bull Case, Bear Case and Scenario Framework

The bull case starts with REGAL. If GPS shows a statistically and clinically meaningful overall-survival benefit in AML patients in second complete remission, SELLAS could be revalued around a potential first-in-class immunotherapeutic in a setting with no approved maintenance standard. Positive data would open regulatory planning, a possible BLA and, plausibly, strategic interest from companies with hematology infrastructure. SLS009 would then become additive rather than defensive: a second AML program advancing behind a successful late-stage asset.

A second bull layer is financial: $138.3 million of cash at June 30, 2026, no ATM sales and company guidance that cash funds planned operations for at least twelve months from the Q2 filing give SELLAS room either to prepare regulatory and commercial work after a positive REGAL or to protect SLS009 after a negative one.

The bear case is equally direct. REGAL can miss statistical significance, show a benefit too small to matter clinically, produce subgroup ambiguity or raise safety questions. Because GPS is the lead value driver, a failed or ambiguous result would likely hit the shares hard, and SLS009 alone may not support the current event-driven valuation. Capital structure is the second bear layer: warrant exercises lifted the share count to 201.95 million by August 10, the ATM remains live, and a negative readout would make any future financing far more dilutive. Even a positive readout would bring new capital needs for manufacturing, regulatory work and launch preparation.

The red flags are not hidden: SELLAS is pre-commercial, REGAL is binary, SLS009 is promising but not definitive, dilution has been material, and cancer immunotherapy outside the checkpoint class has a mixed record in randomized trials. These points do not invalidate the opportunity; they define it.

What Would Falsify This Reading

This reading rests on four claims: REGAL is close to its final-analysis trigger, the balance sheet funds SELLAS through both AML readouts without new equity so far, SLS009 is a credible second AML asset, and the 3D Medicines dispute is closed with the licence intact. Each of them could turn out to be wrong, and these are the observations that would show it.

• A REGAL count still at 78, or a change to the 80-event trigger, well into 2027 would mean the trial is not as close to its final analysis as the May 11 count suggests.
• ATM sales or a new equity offering before REGAL topline would contradict the reading that the June 30 cash removes near-term financing pressure.
• Operating cash use well above the first-half pace of $16.4 million in six months, about $8.2 million a quarter, would shorten the runway that the several-year estimate assumes; in the Q3 Form 10-Q the comparable nine-month figure would be about $24.6 million.
• First-line SLS009 topline moved out of Q4 2026, or response rates well below the relapsed/refractory signal, would weaken the case for SLS009 as a second pillar.
• A disclosure that the Greater China licence has been amended or terminated would reverse the reading that the arbitration ended with the licence and its $191.5 million of potential milestones in place.

None of these is a prediction. They are the observations that would make the reading above wrong, listed so that a reader can check them rather than take the reading on trust.

02 Extended status

Next confirmed catalyst: no announcement that REGAL has reached its pre-specified 80th event. The last count dated by SELLAS is 78 of 80 as of May 11, 2026. The August 11 Q2 release says the company is approaching the threshold and will announce it when it occurs; on August 18, licensing partner 3D Medicines told the Hong Kong Stock Exchange that the global trial of 3D189, the Greater China designation for GPS, had accumulated 78 events against the 80-event target. That statement should not be read as an independent, later count: in its interim results announcement of August 31 and its Interim Report 2026 published on September 30, 3D Medicines ties the same 78 events to May 11, 2026 and to the first half of 2026, so the August 18 figure is most likely a restatement of the count SELLAS published on May 12. The last dated count therefore remains SELLAS’ 78 as of May 11. The August 11 Q2 release adds only that the trial is approaching event 80; on August 7, 2025 the company had said it expected event 80 by the end of 2025, and six events accrued between December 26, 2025 and May 11, 2026. Neither party has announced event 80, database lock, unblinding or topline results through October 3, 2026.

The September 25 release in detail. SELLAS reported that researchers at the University of Wisconsin–Madison tested SLS009 (tambiciclib) in patient-derived organoid models of pancreatic ductal adenocarcinoma, focusing on MYC-amplified tumors, including a model resistant to the RAS inhibitor daraxonrasib (RMC-6236). With a 24-hour SLS009 exposure meant to approximate pharmacokinetics in patients and assessment at 72 hours, SLS009 at 200 nM induced 17.9% apoptosis versus 2.8% with daraxonrasib and 14.5% necrosis versus 2.7%; the two drugs together produced 36.5% apoptosis and 30.6% necrosis. A combination with the BET inhibitor ZEN3694 was described as showing synergistic activity and sustained suppression of MYC. The three posters (A036, B127 and B043) were presented on September 27 at the AACR Conference on Pancreatic Cancer in San Diego. Dragan Cicic, M.D., named in the release as Senior Vice President, Clinical Development (the June 25 Form 8-K describes him as Senior Vice President and Chief Development Officer), called the findings encouraging preclinical evidence that CDK9 inhibition may enhance RAS-directed therapy.

These are laboratory results in organoids, not data from patients, and the release contains no REGAL event count and no AML clinical readout. Their value is directional: they support the plan, first stated on August 11, to prepare clinical development in pancreatic cancer with an academic institution, which has not yet been announced as a registered trial.

What did not change. SELLAS has filed no 8-K, 10-Q or registration statement since August 11, 2026 (EDGAR, as of October 3), so cash ($138.3 million at June 30), the share count (201.95 million at August 10) and SLS009 first-line enrollment (28 of 80 at August 10) remain at their Form 10-Q dates. The 3D Medicines arbitration closed on August 18, when the partner announced that the HK$7,983,004.42 award, due by August 7, had been paid in full. The ClinicalTrials.gov REGAL record was last updated on October 1, 2025 and still lists an estimated primary completion of December 2025, so the registry is not a guide to timing.

Core verification: SELLAS, September 25, 2026 · SELLAS Q2 2026 results (Exhibit 99.1) · Q2 2026 Form 10-Q · 3D Medicines (HKEX: 1244) announcement of August 18, 2026 · 3D Medicines interim results announcement, August 31, 2026 · 3D Medicines Interim Report 2026, September 30, 2026 · SELLAS filings on EDGAR

03 Extended Summary: Why SELLAS Matters Now

SELLAS Life Sciences Group is a late-stage oncology company built around two assets: galinpepimut-S, or GPS, a WT1-targeting immunotherapeutic in the pivotal Phase 3 REGAL study, and SLS009, or tambiciclib, a highly selective CDK9 inhibitor in AML. Both have a readout ahead, but only one has a guided window. REGAL’s final analysis starts when the 80th event occurs; the last dated count is 78 as of May 11, 2026. SLS009’s randomized first-line Phase 2 trial, 28 of 80 patients enrolled as of August 10, is guided to topline data in Q4 2026.

The balance sheet is the clearest change of 2026. Cash reached $138.3 million at June 30 after $82.9 million of proceeds from 48.77 million warrant exercises in the first half, with no ATM sales. The share base rose to 201.95 million by August 10, so the improvement came with dilution. The September 25 pancreatic organoid data widen the SLS009 story but are preclinical. The framing stays balanced: SELLAS is better funded and more diversified than a year ago, while REGAL’s outcome remains binary and SELLAS remains blinded to the trial’s pooled efficacy and survival data.

04 Company Overview: A Late-Stage Oncology Story Built Around AML

SELLAS is headquartered in New York and describes itself as a late-stage clinical biopharmaceutical company focused on novel therapies for a broad range of cancers. In practice, the market values it through acute myeloid leukemia, because both lead programs are AML programs. GPS is in a pivotal Phase 3 survival study in AML patients who reached complete remission after second-line salvage therapy. SLS009 is being studied in relapsed/refractory AML and in newly diagnosed high-risk AML patients unlikely to benefit from standard azacitidine plus venetoclax.

GPS, licensed from Memorial Sloan Kettering Cancer Center, targets the Wilms Tumor 1 protein (WT1), which is overexpressed in several hematologic malignancies and solid tumors. It has been studied in AML, mesothelioma, multiple myeloma and other settings, but the defining question is whether REGAL provides the randomized, registrational evidence needed to make it an approvable product.

SLS009, licensed from GenFleet Therapeutics in 2022 for territories outside Greater China, changed the shape of the company. It addresses a different problem with a different mechanism: transcriptional survival signals in high-risk AML biology, including resistance to venetoclax. The two assets do not repeat one scientific bet; they cover different stages of the disease. SELLAS has no marketed product, so its value rests on readouts, regulatory probability, financing flexibility and execution, which is why event-count updates, conference abstracts and warrant exercises move the shares.

Regulatory designations. According to the Q2 2026 Form 10-Q, GPS holds FDA Orphan Drug designations and EMA orphan medicine designations in AML, malignant pleural mesothelioma and multiple myeloma, FDA Fast Track designations in the same three indications and, since October 2024, FDA Rare Pediatric Disease designation for pediatric AML. SLS009 holds FDA Orphan Drug designations in AML and peripheral T-cell lymphoma (PTCL), FDA Fast Track designations in relapsed/refractory AML and relapsed/refractory PTCL, FDA Rare Pediatric Disease designations for pediatric acute lymphoblastic leukemia (June 2024) and pediatric AML (July 2024), and EMA orphan designations in AML (June 2024) and PTCL (July 2024). Designations of this kind bring procedural and commercial advantages, such as closer FDA interaction under Fast Track and orphan market exclusivity if a product is approved, but none of them says anything about whether a drug works.

05 The Full Story So Far: From WT1 Immunotherapy to a Two-Asset AML Narrative

The SELLAS story began with GPS and the idea that WT1, overexpressed in many cancers but scarcely present in most normal adult tissue, could be an immunotherapy target. Over time the market narrowed its attention to the program closest to a decisive catalyst: GPS in AML. REGAL was designed to test it in patients in second complete remission who are not proceeding to transplant, a group in which remission after salvage therapy does not equal cure and relapse risk stays high.

SELLAS announced the completion of REGAL enrollment in March 2024, as its Q2 2026 Form 10-Q recounts; its August 7, 2025 release dates completion to April 2024 with 126 patients randomized, while the ClinicalTrials.gov record lists 127. The study is open-label and event-driven, with the final analysis after 80 deaths. The protocol also called for an interim safety, efficacy and futility analysis after 60 events: that threshold was reached in December 2024, and on January 23, 2025 SELLAS announced a positive outcome, with the Independent Data Monitoring Committee recommending that the trial continue without modification. On August 7, 2025 SELLAS reported a further, periodic IDMC review with the same recommendation, and its annual report states that the committee has met several times and recommended continuation in each instance. Our reading: these recommendations mean no stopping boundary was crossed, for harm, futility or overwhelming benefit; they are not a declaration of efficacy. In the same August 7, 2025 release SELLAS said it expected the 80th event by the end of 2025. On December 29, 2025 it reported 72 events as of December 26, below that expectation. Traders read the slower pace as a possible sign of longer survival on GPS; the narrower reading is that it is compatible with that hypothesis without proving it. On May 12, 2026 SELLAS reported 78 events as of May 11, leaving two to the trigger.

In parallel, SLS009 turned the company into a two-asset AML story. CDK9 regulates transcription of short-lived survival proteins such as MCL-1, a known route of resistance to venetoclax. At ASH 2025 SELLAS reported that SLS009 plus azacitidine and venetoclax achieved a 46% overall response rate in 35 evaluable relapsed/refractory AML-MR patients previously treated with venetoclax-based regimens, including 29% CR/CRi, with median overall survival of 8.9 months in the least pretreated cohort. Those results supported expansion into newly diagnosed high-risk AML, where the first patient was enrolled in March 2026, and in 2026 the company added preclinical work, including a poster at the AACR Annual Meeting on April 21, 2026, announced on March 17, and the pancreatic-cancer organoid data of September.

06 REGAL and GPS: The Central Binary Catalyst

REGAL is an open-label, randomized Phase 3 study of GPS versus investigator’s choice of best available therapy as maintenance in AML patients who reached complete remission after second-line salvage therapy (CR2/CRp2). The primary endpoint is overall survival, and the final analysis is triggered by the 80th event, meaning death. Overall survival is among the hardest and most meaningful endpoints in oncology, but event-driven timing is not under the company’s control, which is why the count has become a market variable in its own right.

The population matters. Remission after salvage therapy is clinically meaningful, yet it usually follows aggressive disease and prior treatment failure, and patients who do not proceed to transplant have no approved maintenance standard. GPS is meant to stimulate immune recognition of WT1-expressing leukemic cells and keep pressure on residual disease after remission. The challenge is historical: cancer vaccines and immunotherapeutics outside the checkpoint class have often failed to produce decisive randomized results, and REGAL is the trial built to separate hypothesis from proof.

Key interpretation: 78 of 80 events places REGAL very close to the final-analysis trigger. It does not reveal which arm is doing better. REGAL is open-label, so treating physicians know each patient’s assignment, but SELLAS states in its Form 10-Q that it remains blinded to all efficacy and survival outcome data: the pooled event count reaches it from its contract research organization, and no one outside the formal analysis process can know the outcome before the final analysis is run.

Management has also argued its case outside formal disclosures. In a July 9 post on his LinkedIn account — social-media commentary, not a SELLAS press release or SEC filing, and treated here as unverified — CEO Angelos Stergiou rejected the reading that a delayed 80th event means the control arm is outperforming, noting that the CR2 maintenance setting has no approved standard therapy and arguing that slower event accrual is compatible with a durable effect on the active arm. In a later July post he wrote that SELLAS was still approaching the threshold, had entered a quiet period on specific clinical updates and was preparing database lock and BLA/CTD regulatory work. These are executive opinions in an unverified channel, not company disclosures and not outcome evidence; the BLA preparation itself is confirmed separately by the Form 10-Q, which attributes part of the higher R&D spending to it.

After event 80 the sequence is database lock, blinded data review, statistical analysis, unblinding and topline disclosure, so the trigger and the answer are separate announcements. The bull reading rests on the IDMC continuation recommendations, including the positive interim analysis of January 2025, the longer-than-expected timeline, the unmet need and earlier clinical rationale. The bear reading is that a longer timeline can also reflect better survival in both arms, patient mix or chance, and that a study can take longer and still fail. A miss would not erase SLS009, but it would damage the near-term story and financing options.

07 SLS009 / Tambiciclib: The Second Pillar and the Venetoclax-Resistance Angle

The GenFleet license also carries obligations beyond trial spending. By June 30, 2026, SELLAS had paid the entire $10.0 million upfront and technology-transfer fee. Further payments depend on milestones: up to $48.0 million for development and regulatory achievements across as many as three indications, and up to $92.0 million for sales thresholds. Tiered royalties range from low to high single-digit percentages of annual SLS009 net sales in the licensed territory. These contingent ceilings are not current payable balances. SELLAS Form 10-Q for the quarter ended June 30, 2026.

SLS009 is what makes SELLAS more than a one-trial setup. CDK9 drives transcription of short-lived proteins that cancer cells depend on, and one of the most discussed in AML is MCL-1, often linked to resistance to venetoclax. Venetoclax plus azacitidine is the standard backbone for patients unfit for intensive chemotherapy, but many relapse or become refractory, and outcomes after venetoclax failure are poor. If resistance involves a shift from BCL-2 dependence toward MCL-1, a selective CDK9 inhibitor that suppresses those survival signals has a clear rationale. SELLAS has reported reductions in MCL-1 and survivin in AML cell lines and activity in adverse-risk subtypes.

The ASH 2025 data drove the reappraisal. In relapsed/refractory AML-MR patients previously treated with venetoclax-based regimens, SLS009 plus azacitidine and venetoclax produced a 46% overall response rate among 35 evaluable patients, including 29% CR/CRi, with response rates of 48% in ASXL1-mutated and 57% in TP53-mutated patients and no dose-limiting toxicities or treatment-related deaths in the reported dataset. Median overall survival reached 8.9 months in the least pretreated cohort and had not been reached in patients with one prior line. The study was small and not randomized, response does not always translate into survival, and cross-trial comparisons are fragile; the signal was nonetheless strong enough to justify earlier-line development.

The ASH subset sits on a broader relapsed/refractory dataset. In its topline report from that Phase 2 trial, SELLAS said the study met its primary endpoints, with an overall response rate of 33% across 54 evaluable patients, 40% at the 30 mg twice-weekly dose and 44% in AML-MR patients at that dose. At an End-of-Phase-2 meeting announced on July 15, 2025, according to the company, the FDA recommended that SELLAS proceed into a trial including newly diagnosed, first-line AML patients eligible for azacitidine and venetoclax, a setting where the agency noted clinical benefit might be greatest; that recommendation shaped the first-line design described below.

The randomized first-line Phase 2 trial is designed for 80 newly diagnosed patients across a predictive-biomarker cohort and an early venetoclax-resistance cohort identified through transcriptomic, genomic and proteomic models. The Q2 Form 10-Q reports 28 patients enrolled as of August 10, 2026, with enrollment ongoing in the U.S.; the August 11 second-quarter release guides topline data to Q4 2026. The ClinicalTrials.gov record cited by SELLAS (NCT04588922, updated September 3, 2026) lists an estimated primary completion of December 30, 2026 for the broader Phase 1/2a study, and its arm list shows the predictive-biomarker cohort (Group 4) recruiting while the early venetoclax-resistance cohort (Group 5) is not yet recruiting. That matters for reading the guidance: a Q4 2026 topline would come from a trial about a third enrolled at the last published count and with one of its two cohorts not yet open on the registry, so its size and scope remain undisclosed. An agreement announced on January 14, 2026 with IMPACT-AML, a pan-European AML network that will sponsor and conduct its own SLS009 study, is meant to add European sites; SELLAS’ full-year 2025 release guided to approximately 40 European patients, with enrollment in the second quarter of 2026; the Q2 Form 10-Q now says SELLAS “expanded” European patient access, but no separate update on that study has been published, and no IMPACT-AML study of SLS009 appears on ClinicalTrials.gov. Moving earlier in the disease is more competitive but potentially more valuable than a narrow salvage setting.

The pancreatic branch is newer. After describing single-agent activity in PDAC cells resistant to leading RAS inhibitors on August 11, SELLAS quantified it in patient-derived organoids on September 25 (section 02). Resistance to RAS inhibitors is a growing problem in pancreatic cancer, which explains the interest, but organoid activity does not establish efficacy in patients; the next verifiable milestone would be a registered clinical trial.

The bear case is that SLS009 remains early. CDK9 inhibition has attracted interest for years, and tolerability, dosing, selectivity and durability have been recurring problems across the class. SELLAS argues that SLS009 is differentiated on selectivity and tolerability; larger datasets, starting with the Q4 2026 first-line topline, will have to show it.

08 Financial Position, Burn Rate and Dilution Risk

SELLAS separately reported an accumulated deficit of $293.0 million at June 30, 2026. SELLAS Form 10-Q for the quarter ended June 30, 2026.

SELLAS had $138.3 million in cash and cash equivalents at June 30, 2026, up from $71.8 million at December 31, 2025, a year-end figure SELLAS first gave as a preliminary estimate in a Form 8-K filed on January 8, 2026, which also reported about $26.5 million of warrant proceeds received after year-end and 170,282,026 shares outstanding at January 7, and confirmed with its full-year results on March 19. The company likewise first gave the June 30 figure as a preliminary, unaudited estimate in a Form 8-K filed on July 27 and confirmed it in the Q2 report on August 11. The increase came mainly from warrant exercises: in the first half, holders exercised 48.77 million warrants for approximately $82.9 million, at a weighted-average exercise price of $1.70.

Q2 R&D expense was $6.3 million versus $3.9 million a year earlier, and G&A was $4.4 million versus $3.0 million. Interest income of $1.0 million, up from $0.3 million, offset part of the increase, leaving a quarterly net loss of $9.6 million, or $0.05 per share, against $6.6 million and $0.07 a year earlier. First-half R&D was $11.4 million and the first-half net loss $18.0 million. Net cash used in operating activities was $16.4 million in the first half, almost unchanged year over year: $8.8 million in the first quarter and $7.6 million in the second.

The 10-Q attributes the first-half R&D increase mainly to $2.3 million of higher GPS manufacturing costs, $0.8 million of added clinical and regulatory consulting, $0.4 million of higher GPS trial costs and $0.4 million of higher SLS009 trial costs, and management expects R&D to keep rising as it prepares a potential GPS BLA and advances first-line SLS009. That preparation is rational, but a BLA still depends on positive REGAL results and FDA agreement.

The arbitration with 3D Medicines is now accounted for. The July 27 Form 8-K states that the July 24 decision dismissed SELLAS’ claims and allocated approximately $1.0 million of 3D Medicines’ costs to SELLAS; the 10-Q splits it into about $0.7 million of legal fees and $0.3 million of arbitrator and HKIAC costs, and the full approximately $1.0 million was recognized in Q2 G&A. The 8-K adds that $191.5 million of potential future milestones remained under the licence as of March 31, 2026, including the $13.0 million that had been in dispute, and the 10-Q gives the same $191.5 million at June 30, 2026. Those milestones are variable, outside SELLAS’ control and not revenue.

The per-share cost is visible. Common shares outstanding rose from 153.10 million at year-end 2025 to 201.95 million at August 10. Year over year the change is starker: 100.37 million shares at June 30, 2025 against 201.92 million at June 30, 2026, roughly double, and the Q2 weighted-average count used for loss per share was 189.2 million against 98.6 million a year earlier, which is why a larger net loss produced a smaller loss per share. At June 30, 2.65 million options, 3.33 million RSUs and 18.94 million shares reserved for future grants sat alongside the 9.71 million remaining warrants. The ATM is a sales agreement with TD Cowen dated March 20, 2026 for up to $150 million, on an automatic shelf registration on Form S-3ASR filed the same day, available to SELLAS as a well-known seasoned issuer. The 10-Q, filed August 11, states that no shares had been sold through it to date, and no later SEC filing reports a sale through October 3, 2026. Form S-3ASR, March 20, 2026

SELLAS says current cash funds planned operations for at least twelve months from the issuance of the Q2 statements. At the first-half pace of operating cash use, $138.3 million would last several years, a Merlintrader calculation that assumes flat spending, which management does not expect as BLA preparation and SLS009 enrollment add costs.

09 Management, Execution and Governance

SELLAS is led by founder, President and Chief Executive Officer Angelos M. Stergiou, M.D., Sc.D. h.c., who previously co-founded Genesis Life Sciences, a health-economics, pricing-reimbursement and market-access company. That background matters because, if REGAL is positive, the next problems are regulatory, access, pricing and manufacturing decisions. The team includes Dragan Cicic, M.D., described in the June 25, 2026 Form 8-K as Senior Vice President and Chief Development Officer and in the September 25 release as Senior Vice President, Clinical Development; John T. Burns, C.P.A., Senior Vice President and Chief Financial Officer; Andrew Elnatan, Senior Vice President of Regulatory Affairs, CMC and Quality; and Stacy E. Yeung, Vice President, General Counsel and Corporate Secretary. Regulatory and CMC leadership is what turns a positive trial into a credible filing.

On the constructive side, SELLAS completed REGAL enrollment, cleared the pre-specified interim analysis and every IDMC review so far, kept reporting the event count as the timeline moved, strengthened the balance sheet without using the ATM, presented SLS009 data at ASH, started first-line SLS009 enrollment, signed IMPACT-AML and added pancreatic preclinical work. On the skeptical side, it has a long history of financing needs and heavy dilution, it lost the 3D Medicines arbitration in July, and its valuation depends on future events. At the Annual Meeting on June 16, 2026, whose results SELLAS reported in a Form 8-K filed on June 18, stockholders approved 20 million additional shares under the 2023 Amended and Restated Equity Incentive Plan, which the Q2 Form 10-Q now calls the 2026 Amended and Restated Equity Incentive Plan, by about 42.9 million votes for to 27.3 million against; at June 30 the plan allowed up to approximately 24.9 million shares, of which 18.94 million remained available for future grants. About 15.9 million votes were cast against the advisory say-on-pay resolution. On June 16 the CEO also received a grant of 1,065,000 restricted stock units, vesting 25% on each December 1 starting in 2026; after it, his Form 4 shows 1,759,183 shares held directly. Executive agreements dated June 24 and disclosed in a Form 8-K filed on June 25 amended severance and change-of-control arrangements for the CEO, CFO and Chief Development Officer, a governance item that is not evidence of a transaction.

No director or officer has reported a sale of SELLAS shares in 2026: the year’s Forms 4 are the January 7 grants of 50,000 restricted stock units to each director and 300,000 each to Cicic and Burns, and the CEO’s June 16 grant. The Q2 Form 10-Q (Part II, Item 5) does disclose that three directors adopted Rule 10b5-1 sell-to-cover plans for taxes on vesting awards — Varian for up to 12,500 shares (May 15), Scheinberg for up to 20,000 (May 18) and Van Nostrand for up to 12,500 (June 11) — plans, not completed sales. The board consists of Varian (chair), Scheinberg, Van Nostrand, Wasman, Kalin and Stergiou, and the auditor is Baker Tilly, successor to Moss Adams. Merlintrader has found no Form 144, no Schedule 13D and no litigation other than the concluded 3D Medicines arbitration in the public record through October 3, 2026.

The real test lies ahead: precise communication now, while the company remains blinded to REGAL’s pooled outcome data, and capital allocation after the data, in either direction.

10 Timeline of Key Developments

11 Ownership, Analysts and Retail Sentiment

SELLAS has the ownership profile of a catalyst-sensitive small-cap biotech: index funds, warrant holders, event-driven funds, options traders and a large retail following all react to the same binary event. Three passive Schedule 13G filings add real data points, and all have to be read from the filings themselves.

Vanguard Capital Management filed on July 31, reporting 9,666,278 securities, or 5.19% of the class as of June 30, 2026, with 1,400,173 shares of sole voting power; the filing describes the position as held in the form of warrants. That description is hard to reconcile with the company’s own figures: the Q2 Form 10-Q shows only about 9.71 million warrants outstanding in total at June 30, so a single holder owning 9.67 million of them looks implausible, and in our reading the description is more likely a filing error than information about who holds the remaining warrants. State Street Corporation filed on August 7, reporting 12,996,558 shares, or 7% of the class as of June 30, with shared voting power over 12,677,559 shares and shared dispositive power over all of them. Both are Rule 13d-1(b) filings by institutions holding in the ordinary course, without a control purpose. Earlier, on April 24, 2026, BlackRock filed a Schedule 13G/A reporting 12,136,331 shares, or 6.8% of the class as of March 31, 2026, also a passive filing.

Ownership reading: large index-fund holders are a normal consequence of a market capitalization in the billions and of index membership; Finviz lists SLS in the Russell 2000. These filings are not evidence of open-market conviction buying, access to unblinded data or an acquisition.

Market-data aggregates read on Finviz on October 2, 2026 show institutional ownership of 36.72% and insider ownership of 1.11%. Short interest was 59,068,630 shares at the September 15, 2026 settlement date, 29.58% of a 199.70 million-share float (Finviz) and 29.25% of the 201.95 million shares outstanding (Merlintrader calculation), equal to 8.6 days to cover per Nasdaq, up from 57.93 million at August 31. Any sell-side target on SELLAS is a scenario-dependent opinion on a trial whose outcome is not yet known, and it can change sharply after REGAL data.

Retail sentiment remains intense. On October 2, 2026, Stocktwits showed 90.98% of sentiment-tagged messages as bullish, while its normalized sentiment score was 47, labeled neutral, with 62,147 users watching the stream. The tagged subset is one-sided; the broader normalized signal is not. Dominant themes are event-80 timing, the theory that slower deaths mean benefit on the active arm, buyout speculation and the institutional filings. These are opinions of retail traders and non-professional investors, not evidence.

12 Rumor Monitor: What Is Confirmed, What Is Inference and What Is Pure Speculation

SELLAS sits in an information vacuum that produces rumors almost automatically: the trial is close to a mechanical trigger, management has described a quiet period on clinical specifics in social-media posts, executive contracts contain change-of-control language, and new institutional filings keep appearing. Each fact can feed a plausible story; plausibility is not confirmation. The table separates confirmed facts, reasonable inference and unsupported rumor, based on SELLAS releases and SEC filings through October 3, 2026.

Rumor rule for this coverage: no acquisition claim, readout date, hidden-data theory or outcome prediction is treated as fact unless a SELLAS filing, a company press release, a regulatory source or another directly attributable primary document supports it. A company this close to an event-driven final analysis should prepare database-lock workflows, regulatory documents and financing options before knowing the result; turning that prudence into proof of success is the mistake. Strategic optionality stays on the board, but until the disclosure standard changes, the buyout story belongs in the rumor box.

13 Upcoming Catalysts and What to Watch

The first catalyst remains a formal SELLAS announcement that REGAL has reached the 80th event, a mechanical trigger rather than the efficacy result. The second is the post-event sequence ending in topline disclosure, where the decisive evidence will be the overall-survival hazard ratio, confidence interval and p-value, median survival if mature, the shape of the curves, subgroup consistency and safety.

The third catalyst is the first-line SLS009 Phase 2 topline, guided to Q4 2026. Enrollment stood at 28 of 80 on August 10, the registry (updated September 3) still lists the early venetoclax-resistance cohort as not yet recruiting, and the company has not said how many patients the topline will include; the useful measures are CR/CRi, duration, MRD if disclosed, survival, safety and whether the biomarker cohorts separate responders. The fourth is follow-through on pancreatic cancer after the September 25 organoid data: a named academic partner, a protocol or a trial registration would be the first clinical step. The fifth is capital: the Q3 Form 10-Q, normally due in November, will show how fast BLA preparation and trial spending consume the $138.3 million and whether any shares were sold through the ATM.

14 Insiders, Institutions and Capital Structure: How to Read the Ownership Picture

The capital structure changed fast in 2026, so ownership percentages move quickly and are best read through filings rather than snapshots. The largest disclosed warrant wave has already converted: 48.77 million warrants were exercised in the first half for $82.9 million, only 9.71 million remained at June 30, and the share count reached 201.95 million by August 10. SELLAS is better funded, and each share is a more diluted claim than at year-end 2025.

Insider ownership is small, about 1.11% on the Finviz aggregate of October 2, 2026, and management is compensated largely in equity, which is normal for a development-stage biotech. Form 4 filings, grants and any open-market purchases around REGAL deserve attention. The $150 million ATM should be watched without being exaggerated: unused as of the Q2 10-Q, it can be a rational funding tool after favorable data or an overhang if used into weakness. The documents that tell the real story are the 10-K and 10-Q, S-3 and ATM filings, financing 8-Ks, Form 4s and 13G/13D reports.

The remaining overhang in detail. Note 7 of the Q2 Form 10-Q splits the 9.71 million warrants left at June 30 into three groups: about 4.06 million October 2025 inducement warrants at $2.00 expiring in October 2030, about 4.66 million from the March 2024 registered direct offering at $1.41 expiring in September 2029, and about 0.99 million other warrants at a weighted $1.73 expiring between April 2027 and January 2029. All are struck far below the October 2, 2026 close of $11.74, and if every one were exercised SELLAS would receive roughly $16.4 million, a Merlintrader calculation, small next to $138.3 million of cash; about 27,000 more were exercised after June 30 at a weighted $0.75. Beyond the warrants sit 2.65 million options, 3.33 million RSUs and 18.94 million shares available under the 2026 Amended and Restated Equity Incentive Plan, plus the unused $150 million ATM with TD Cowen on the March 20, 2026 automatic shelf. The ownership side of the register shows three passive filers: BlackRock with 12,136,331 shares, 6.8% at March 31, 2026; State Street with 12,996,558 shares, 7% at June 30; and Vanguard with 9,666,278 securities, 5.19% at June 30, described in its filing as warrants, which is hard to square with the 9.7 million warrants outstanding in total. Insider activity in the period consists of the CEO’s June 16 grant of 1,065,000 RSUs and the adoption by three directors of Rule 10b5-1 sell-to-cover plans; no sale has been reported on Form 4 in 2026. Merlintrader has found no Form 144 and no Schedule 13D through October 3, 2026, and SELLAS has filed nothing with the SEC since its August 11 Form 10-Q.

15 What Would Make the Story Stronger — and What Would Break It

The strongest version of the story needs more than a headline that REGAL is positive: a clean overall-survival benefit, clearly separated Kaplan-Meier curves, a hazard ratio and p-value that leave little ambiguity, a safety profile suited to a vulnerable AML population, and a credible regulatory path with BLA, CMC and timing. It would get stronger again if first-line SLS009 shows response depth, durability and evidence that the biomarker strategy picks out patients who need more than AZA/VEN.

The story would weaken sharply if REGAL misses, forcing a revaluation around SLS009, cash and remaining optionality; an ambiguous result could be punished almost as hard. The second way it weakens is capital execution: aggressive raising at weak prices, poor communication around the ATM or dilution dominating the post-data narrative. The third is scientific overextension: a good SLS009 signal does not validate every CDK9 hypothesis, and organoid activity in pancreatic cancer is not a solid-tumor program yet. The fourth is the licence: the arbitration cost is settled, but the $191.5 million of variable Greater China milestones depends on development decisions SELLAS does not control.

16 Merlintrader Bottom Line

SELLAS is a high-risk, high-catalyst biotech with more substance than a momentum trade. It has a pivotal, open-label Phase 3 survival trial waiting on its 80th event, with no date and no count published since May 11, and a second AML program guided to topline data in Q4 2026 — the only readout with a guided window, from a trial 28 of 80 enrolled at the last count — new preclinical pancreatic data, $138.3 million of cash at June 30 and no ATM sales reported. It also has a share count above 201 million, a lost arbitration and a rumor cycle that keeps running ahead of the verified record.

Three questions matter more than daily price noise. Can REGAL show a real survival benefit for GPS in AML CR2/CRp2? Can SLS009 become a credible AML program beyond a small relapsed/refractory dataset? Can management turn a stronger balance sheet into value-preserving execution rather than another dilution cycle? The catalyst is real and the science coherent, but SELLAS itself remains blinded to REGAL’s pooled outcome data, event timing is not efficacy, social sentiment is not data, and a stronger balance sheet is not permanent de-risking.

17 Related Merlintrader Reading

• SELLAS March 19, 2026 update
• SELLAS February 23 update
• SLS January 31 update
• Previous SELLAS research note
• Original SELLAS stock overview
• Who Will Be the Next Moderna? Platform ranking including $SLS
• Merlintrader Free Biotech Catalyst Calendar

The block below is a snapshot of the Stocktwits flow, with its date. These are opinions of retail traders and non-professional investors, not analyst research, and they measure attention and how one-sided positioning has become rather than anything about the business.